YOLFTbeta
Voronoi Co. Ltd.

Voronoi Co. Ltd.

310210 · KQ · Healthcare / Biotechnology

111,000.00KRW+1300.00 (+1.19%)

Price History

Full chart

Market Stats

Previous Close109,700.00
Open111,400.00
Day Range109,400.00 – 119,200.00
52-Week Range97,500.00 – 375,500.00
Volume81.64K
Market Cap1.95T
P/E (TTM)0.00
Forward P/E0.00
EPS-3,762.73
Dividend Yield0.00%
Beta1.56
50-Day Avg142,886.00
200-Day Avg211,479.50

About

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Daekwon Kim
  • Employees169
  • HeadquartersS-18, 32, Songdogwahak-ro, Incheon, South Korea, 21984, Korea
  • Websitehttps://voronoi.io

Leadership

  • Mr. Daekwon KimCEO & Director
  • Mr. Sangjin WooCOO & Director · b. 1976
  • Mr. Jaeyoung AhnCBO, President of Voronoi USA, Inc., & Head of U.S. Operations
  • Mr. Hyuntae KimCEO & Director · b. 1976
  • Mr. Sangjin LeeChief Financial Officer
  • Mr. Hosey Hwang C.P.A.Director of Accounting
  • Mr. Sunghwan Kim Ph.D.Chief Science Officer & Director of Biology Research
  • Dr. Yin Zhang M.D.Chief Medical Officer
  • Hwankeun ChoiExecutive Officer of Sub
  • Jungbeom SonExecutive Officer · b. 1976

Financials

Income Statement

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue300.73M6.18B14.78B9.77B007.51B
Growth (%)-+1955.04%+139.22%-33.93%-100.00%--
Gross Profit300.73M6.18B14.78B9.77B--7.51B
Gross Margin100.00%100.00%100.00%100.00%--100.00%
Operating Expense54.51B33.20B29.88B27.63B--61.90B
Operating Income-54.21B-27.02B-15.09B-17.86B-33.70B-36.34B-54.38B
Operating Margin-18024.98%-437.21%-102.10%-182.88%---723.94%
EBITDA----14.28B-31.54B-30.10B-46.20B
EBITDA Margin----146.20%---614.99%
Net Income-50.00B-23.19B-15.10B-19.90B-36.85B-32.61B-42.71B
Net Income Margin-16627.54%-375.20%-102.11%-203.73%---568.49%
R&D-13.41B12.49B11.73B14.46B17.89B31.01B
R&D as % of Total Revenue-217.02%84.50%120.06%--412.82%
Interest Expense-142.42M834.19M2.12B1.91B580.74M2.65B
Interest Expense % of Total Revenue-2.30%5.64%21.74%--35.24%

Balance Sheet

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets30.59B47.71B40.16B63.95B94.65B73.66B171.23B
Total Liabilities16.79B19.62B33.24B29.69B13.31B7.25B67.44B
Total Equity13.80B28.09B6.92B34.26B81.34B66.41B103.80B
Cash-11.95B18.20B11.02B12.86B10.15B35.74B
Net Debt1.12B-7.08B14.16B--1.52B

Cash Flow

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-33.63B-15.89B-17.64B-16.33B-28.85B-29.05B-72.09B
Investing Cash Flow4.31B99.48M-643.42M-38.04B-32.21B22.29B-
Financing Cash Flow27.58B26.72B24.36B47.08B62.96B3.94B-
Capital Expenditure5.69B377.09M583.01M552.41M1.08B1.23B1.68B
Free Cash Flow--16.27B-18.22B-16.89B-29.93B-30.28B-73.78B
FCF to OCF-102.37%103.31%103.38%103.75%104.24%102.33%

Earnings

Report DateJun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------
EPS Actual-400.7999.86-621.42-561.31-440.84-395.52-890.37-384.66-445.02-525.65-493.51-785.15-582.78-767.36-239.53-1202.32-1581.28
Surprise-----------------
Timing-----------------

Key Statistics & Ratios

Market Cap1.95T
Enterprise Value1.89T
Trailing P/E0.00
Forward P/E0.00
Price / Sales468.37
Price / Book28.18
EPS-3,762.73
Book Value3,765.11
Revenue (TTM)4.16B
Gross Profit (TTM)4.16B
EBITDA-78.85B
Profit Margin0.00%
Operating Margin-1947.05%
Return on Equity-119.39%
Return on Assets-54.73%
Shares Outstanding18.37M
Shares Float10.75M
Beta1.56
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 13, 20231.2:1